Gene therapy patients monitored for 15 years in new safety study
NCT ID NCT07424157
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows up to 500 people who have received a gene therapy product from Seattle Children's Hospital. Researchers will track participants for 15 years to watch for any delayed side effects and see how long the therapy lasts in the body. No new treatment is given—this is purely a safety monitoring study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 500 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2026
- Expected to finish
-
Mar 2041
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients who have received treatment with a gene therapy product on an SCTx Sponsored clinical trial.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Enrolled in an SCTx GTP clinical trial; 2. Received or planned to receive an SCTx GTP; 3. Subject and/or legally authorized representative have provided consent/assent for study participation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Car T cell are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Seattle Children's Hospital
RECRUITINGSeattle, Washington, 98105, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- Ultra-Fast CAR-T cells aim to beat back tough lymphomas
- Could a simple drug tame the dangerous side effects of CAR-T cancer therapy?
- CAR-T therapy aimed at tough kidney disease in kids — but trial never started
- Promising CAR-T trial for kids with rare vasculitis pulled before start
- Pedal power: could a bike ride supercharge Cancer-Fighting cells?